Abstract
Protein misfolding and aggregation into insoluble amyloid deposits are often associated with neurodegenerative disorders. In particular, the polyglutamine (polyQ) diseases are inherited disorders triggered by the expansion of the polyQ tract over its physiological length in the involved protein. The molecular mechanism of aggregation from the native protein into amyloids involves several steps including protein misfolding, aggregation into oligomers, which seems to be the most toxic species, and, finally rearrangements into mature fibrils. In the present contribution, we review studies, integrating computational and experimental approaches, of polyQ proteins, as well as of the details of the complicate aggregation mechanisms in which aberrant form of polyQ proteins are involved. These aspects are of crucial relevance for a complete understanding of the onset of polyQ conformational diseases and can also shed light on putative therapeutic targets and future development of aggregation inhibitors.
Keywords: polyQ disease, protein aggregation, protein misfolding, conformational disease, molecular dynamics simulations, aggregation inhibitors, huntingtin, ataxin, polyglutamine (polyQ) diseases, sheet supramolecular structures, Alzheimer's, Parkinson's, amyloids, Amyloid fibrils, protofilaments, hydrogen-bonded amyloid core, antiparallel (AP) structures, ataxins, atrophin-1, synuclein, A amyloid peptide, super-oxide dismutase 1 (SOD1), NMR, cryo-electron microscopy, transmission electron microscopy, electron paramagnetic resonance, fluorescence resonance energy transfer, mutational approaches, size-exclusion chromatography, hydrogen exchange, protein intermediate resolution model (PRIME), polyglutamine expansions, huntingtin (Htt), ataxin-3 (AT-3), ataxin-1 (AT-1), GABAergic medium spiny striatal neurons (MSN), MATLEKLMKAFESLKSF, Nt17, CAG repeat diseases, AXH domain, HBP1, SCA1, CAT, CAG, Machado Joseph Disease, de-ubiquitinating activity, polyubiquitin chains, histone acetyltransferase, N-terminal Josephin domain, ubiquitin interacting motifs (UIMs), 2-3 harpin, K48-linked tetra-ubiquitin chains, Gln, Asn-rich sequences, Sup34-N, Ure2p, circular dichroism, electron microscopy, X-ray diffraction, polyGln tract, Q41 peptide, GNNQQNY, isoenergetic fibrillar form, single molecule force-clamp spectroscopy, Monomeric polyglutamine, OPLSAA/L force field, mesoglobules, Molten oligomers, peptide-rich micro-phases, non-aggregating, aggregating peptides, Transmission Electron Microscopy (TEM), Q20, Q24, aggregates, chimeric proteins, Gln-repeats, chimeric chymotrypsin inhibitor 2 (CI2)-polyQ, pathogenic threshold, non-amyloidogenic protein, replica-exchange MD (REMD), Optimized Potential for Effective Peptide (OPEP), 2 proline helix-breaker residues, UV-CD spectroscopy, polyPro type II-like helix (PPIIlike), arginine [R], lysine [K], aspartate [D], glutamate [E], TANGO algorithm confirms, p53, Q22 peptide, His-Gln-His sequence, AT-3(QHQ), AT-3(Q15), AT-3(Q64), Size Exclusion Chromatography (SEC), heat shock transcription factor 1 (HSF1), geldanamycin, polyQ binding peptide 1 (QPBP1), EGCG (epigallocatechin-3-gallate)
Current Computer-Aided Drug Design
Title: Conformational Diseases: Structural Studies of Aggregation of Polyglutamine Proteins
Volume: 7 Issue: 1
Author(s): Elena Papaleo and Gaetano Invernizzi
Affiliation:
Keywords: polyQ disease, protein aggregation, protein misfolding, conformational disease, molecular dynamics simulations, aggregation inhibitors, huntingtin, ataxin, polyglutamine (polyQ) diseases, sheet supramolecular structures, Alzheimer's, Parkinson's, amyloids, Amyloid fibrils, protofilaments, hydrogen-bonded amyloid core, antiparallel (AP) structures, ataxins, atrophin-1, synuclein, A amyloid peptide, super-oxide dismutase 1 (SOD1), NMR, cryo-electron microscopy, transmission electron microscopy, electron paramagnetic resonance, fluorescence resonance energy transfer, mutational approaches, size-exclusion chromatography, hydrogen exchange, protein intermediate resolution model (PRIME), polyglutamine expansions, huntingtin (Htt), ataxin-3 (AT-3), ataxin-1 (AT-1), GABAergic medium spiny striatal neurons (MSN), MATLEKLMKAFESLKSF, Nt17, CAG repeat diseases, AXH domain, HBP1, SCA1, CAT, CAG, Machado Joseph Disease, de-ubiquitinating activity, polyubiquitin chains, histone acetyltransferase, N-terminal Josephin domain, ubiquitin interacting motifs (UIMs), 2-3 harpin, K48-linked tetra-ubiquitin chains, Gln, Asn-rich sequences, Sup34-N, Ure2p, circular dichroism, electron microscopy, X-ray diffraction, polyGln tract, Q41 peptide, GNNQQNY, isoenergetic fibrillar form, single molecule force-clamp spectroscopy, Monomeric polyglutamine, OPLSAA/L force field, mesoglobules, Molten oligomers, peptide-rich micro-phases, non-aggregating, aggregating peptides, Transmission Electron Microscopy (TEM), Q20, Q24, aggregates, chimeric proteins, Gln-repeats, chimeric chymotrypsin inhibitor 2 (CI2)-polyQ, pathogenic threshold, non-amyloidogenic protein, replica-exchange MD (REMD), Optimized Potential for Effective Peptide (OPEP), 2 proline helix-breaker residues, UV-CD spectroscopy, polyPro type II-like helix (PPIIlike), arginine [R], lysine [K], aspartate [D], glutamate [E], TANGO algorithm confirms, p53, Q22 peptide, His-Gln-His sequence, AT-3(QHQ), AT-3(Q15), AT-3(Q64), Size Exclusion Chromatography (SEC), heat shock transcription factor 1 (HSF1), geldanamycin, polyQ binding peptide 1 (QPBP1), EGCG (epigallocatechin-3-gallate)
Abstract: Protein misfolding and aggregation into insoluble amyloid deposits are often associated with neurodegenerative disorders. In particular, the polyglutamine (polyQ) diseases are inherited disorders triggered by the expansion of the polyQ tract over its physiological length in the involved protein. The molecular mechanism of aggregation from the native protein into amyloids involves several steps including protein misfolding, aggregation into oligomers, which seems to be the most toxic species, and, finally rearrangements into mature fibrils. In the present contribution, we review studies, integrating computational and experimental approaches, of polyQ proteins, as well as of the details of the complicate aggregation mechanisms in which aberrant form of polyQ proteins are involved. These aspects are of crucial relevance for a complete understanding of the onset of polyQ conformational diseases and can also shed light on putative therapeutic targets and future development of aggregation inhibitors.
Export Options
About this article
Cite this article as:
Papaleo Elena and Invernizzi Gaetano, Conformational Diseases: Structural Studies of Aggregation of Polyglutamine Proteins, Current Computer-Aided Drug Design 2011; 7 (1) . https://dx.doi.org/10.2174/157340911793743574
DOI https://dx.doi.org/10.2174/157340911793743574 |
Print ISSN 1573-4099 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6697 |

- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Can't Always Get What you Want? Try an Indirect Route you Just Might Get What you Need: A Study on Access to Genetic Data by Canadian Life Insurers
Current Pharmacogenomics and Personalized Medicine Repurposing of Anti-Diabetic Agents for the Treatment of Cognitive Impairment and Mood Disorders
Current Molecular Medicine Oxidative RNA Damage and Neurodegeneration
Current Medicinal Chemistry After Thalidomide – Do We Have the Right Balance Between Public Health and Intellectual Property
Reviews on Recent Clinical Trials Biomarkers of Oxidative Stress and the Relationship to Cigarette Smoking
Mini-Reviews in Organic Chemistry New Emerging Trends in Protein and Peptide Based Therapeutic Approaches – Part I
Current Protein & Peptide Science Molecular Mechanisms, Proteinopathies and Therapeutic Strategies in Neurodegenerative Disorders
Current Genomics Quercetin in Attenuation of Ischemic/Reperfusion Injury: A Review
Current Molecular Pharmacology Zinc-Permeable Ion Channels: Effects on Intracellular Zinc Dynamics and Potential Physiological/Pathophysiological Significance
Current Medicinal Chemistry Colon Targeted Rifaximin Nanosuspension for the Treatment of Inflammatory Bowel Disease (IBD)
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Selective Divalent Copper Chelation for the Treatment of Diabetes Mellitus
Current Medicinal Chemistry Peripheral Mononuclear Cell Rejuvenation for Senescence Surveillance in Alzheimer Disease
Current Pharmaceutical Design GPCR Binding Technologies: An Overview
Current Topics in Medicinal Chemistry Alcoholism and its Effects on the Central Nervous System
Current Neurovascular Research Intranasal Lipid Particulate Drug Delivery Systems: An Update on Clinical Challenges and Biodistribution Studies of Cerebroactive Drugs in Alzheimer’s disease
Current Pharmaceutical Design The Usefulness and Challenges of Transgenic Mouse Models in the Study of Alzheimers Disease
CNS & Neurological Disorders - Drug Targets Good Epidemiologic Practice in Retinitis Pigmentosa: From Phenotyping to Biobanking
Current Genomics Nicotinamide and its Pharmacological Properties for Clinical Therapy
Drug Design Reviews - Online (Discontinued) The NMDA Receptor as a Therapeutic Target in Major Depressive Disorder
CNS & Neurological Disorders - Drug Targets Review of Antibiotic and Non-Antibiotic Properties of Beta-lactam Molecules
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry